HEFEI,China,Sept. 20,2024 -- Kangpu Biopharmaceuticals,a clinical-stage company based in Hefei,announced today that the Company has successfully completed a bridging clinical study of KPG-818 in healthy subjects in China.
The randomized,double-blind,placebo-controlled,and food effects (FE) study aimed to assess the safety and tolerability of multiple oral doses of KPG-818 in male and female healthy participants over a treatment period of 14 days and a follow-up period of 4 weeks,to characterize the single and multiple oral dose pharmacokinetics (PK) of KPG-818,and to select dosing regimens of KPG-818 for future clinical trials. A total of 30 participants were randomized to three escalating cohorts (n=10 each; 8 KPG-818,2 placebo) receiving 0.15 mg,0.6 mg,2 mg or placebo once daily. In the FE cohort,12 participants received single dose of 0.6 mg KPG-818 with and without food.
KPG-818 is well tolerated in healthy subjects. No serious adverse events (SAEs) were reported. The most common AEs were grades 1-2 of pruritus or rash.
Close to linear PK of KPG-818 was observed in the dosing range of 0.15 mg-2 mg. Similar exposure was observed for KPG-818 under fed/fasted conditions.
KPG-818 is a small molecule modulator of CRBN E3 ubiquitin ligase complex CRL4-CRBN. In the Phase Ib/IIa clinical study in SLE patients (trial ID: NCT04643067) completed in the US,KPG-818 demonstrated promising efficacy and a favorable safety and tolerability profile.
About Kangpu Biopharmaceuticals
Kangpu Biopharmaceuticals,Ltd. is a clinical-stage company focused on the discovery and development of innovative molecular glue-based therapeutics for the treatment of autoimmune diseases,solid tumors,hematologic malignancies and inflammatory disorders. Kangpu has developed a robust pipeline of potential first-in-class and best-in-class drug candidates based on proprietary technology platforms,including NeoMIDES®,gDACS®,and X-SYNERGY®.
For more information,please visit www.KangpuGroup.com
Media Contact: Florence Liu,[email protected]
© OfficialAffairs
